View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.

In trading on Thursday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) entered into oversold territory, hitting an RSI reading of 24.8, after changing hands as low as $377.85 per share.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

In a recent transaction, Vertex Pharmaceuticals Inc.'s (NASDAQ:VRTX) Executive Vice President and Chief Medical Officer, Dr. Carmen Bozic, sold 2,280 shares of the company's common... ByInvesting ...

Shares of Vertex Pharmaceuticals fell more than 10% premarket Thursday, on track to hit lows last seen in early May, ...

VRTX does not currently pay a dividend.

- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ -- Safety profile consistent with ...

Brookdale Senior Living Inc. ("Brookdale" or the "Company") announced today that the Company has recently completed a successful advance refinancing of more than $300 million of the Company's 2027 ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...